Results 61 to 70 of about 6,645 (195)

Psychopathology Associated with Chronic Pruritus: A Systematic Review

open access: yesActa Dermato-Venereologica, 2023
There are no previous studies of the psychopathology associated with different aetiologies of chronic pruritus. A systematic review was performed of cohort and case-control studies comparing healthy controls with patients with chronic pruritus related to
Bárbara R. Ferreira, Laurent Misery
doaj   +1 more source

Therapeutic advances in pruritus as a model of personalized medicine

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Recent advances in itch biology reveal that chronic pruritus arises from distinct neuroimmune pathways driven by cytokines, JAK, BTK and GPCRs. Targeted biologics and small molecule inhibitors such as dupilumab, nemolizumab, remibrutinib and JAK inhibitors precisely modulate these pathways, leading to a new era of personalized therapeutics in pruritus.
Kelsey Auyeung   +2 more
wiley   +1 more source

Dementia Incidence in Patients With Prurigo Nodularis: An Observational Retrospective Cohort Study

open access: yes
JEADV Clinical Practice, EarlyView.
Madison P. Olexson   +3 more
wiley   +1 more source

The SWITCH algorithm: An expert consensus on treat‐to‐target criteria for chronic prurigo

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
The SWITCH project assessed patients' most distressing symptoms and therapy goals, followed by an expert‐based consensus procedure to define T2T criteria for patients with chronic prurigo (CPG)/prurigo nodularis. Based on these validated criteria, a 4‐step SWITCH algorithm was established to enhance CPG therapy outcomes and reduce patient burden ...
Lea S. Stahl   +16 more
wiley   +1 more source

Association between Prurigo Nodularis and Etiologies of Peripheral Neuropathy: Suggesting a Role for Neural Dysregulation in Pathogenesis

open access: yesMedicines, 2020
Background: Prurigo nodularis (PN) is an intensely pruritic skin condition of considerable morbidity. However, the pathogenesis of PN and its association with underlying neuropathy is unclear.
John-Douglas Matthew Hughes   +7 more
doaj   +1 more source

Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Achieving rapid control of itch in atopic dermatitis and prurigo nodularis may minimize symptomatology and disease burden. Analysis of clinical trials in atopic dermatitis and prurigo nodularis showed significantly more patients in nemolizumab versus placebo groups achieved a meaningful clinical response in itch within 48 h, and separation increased ...
Sonja Ständer   +10 more
wiley   +1 more source

Effectiveness of Dupilumab for an Elderly Patient with Prurigo Nodularis Who Was Refractory and Contradicted to Traditional Therapy

open access: yesJournal of Asthma and Allergy, 2021
Taoming Liu, Juan Bai, Su Wang, Shuni Ying, Sheng Li, Jianjun Qiao, Hong Fang Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of ChinaCorrespondence: Jianjun Qiao; Hong ...
Liu T   +6 more
doaj  

Dupilumab Reduces Pruritus in Twins With Sjögren–Larsson Syndrome

open access: yesPediatric Dermatology, EarlyView.
ABSTRACT Sjögren–Larsson Syndrome (SLS), now termed ALDH3A2‐syndromic epidermal differentiation disorder (sEDD), is a rare genetic disorder marked by thickened skin, spasticity, and intellectual disability. Intractable pruritus is a nearly universal and debilitating feature of SLS that remains poorly managed by current therapies. We describe 4‐year‐old
Kennedy Gallagher   +3 more
wiley   +1 more source

Biologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future Directions

open access: yesAllergy, Volume 81, Issue 2, Page 326-344, February 2026.
ABSTRACT Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases worldwide. The clinical presentation of AD is heterogeneous and is characterized by a relapsing and remitting course. Most patients suffer from mild AD while approximately 5% to 20% experience severe disease activity, which often requires systemic treatment ...
Marjolein S. de Bruin‐Weller   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy